College Operations Update in Response to COVID-19 READ MORE  
close skinny banner

Dose-Splitting of Lucentis, Eylea May Pose a Risk to Patient Safety

Posted:May 16th, 2018
Read Time: 1 Min Read

The College is advising all pharmacy professionals that dose-splitting of single use Lucentis or Eylea vials may pose a risk to patient safety. Please view the following correspondence from the National Association of Pharmacy Regulatory Authorities (NAPRA) and Health Canada:

Please be reminded that the Model Standards for Pharmacy Compounding of Non-Hazardous Sterile Preparations and the Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations, developed by NAPRA, have been adopted as the standard for sterile compounding in Ontario.